BIONANO GENOMICS INC (BNGO)

US09075F3055 - Common Stock

0.2093  +0.01 (+3.41%)

Fundamental Rating

2

Taking everything into account, BNGO scores 2 out of 10 in our fundamental rating. BNGO was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of BNGO have multiple concerns. BNGO is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BNGO has reported negative net income.
In the past year BNGO has reported a negative cash flow from operations.
BNGO had negative earnings in each of the past 5 years.
BNGO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -155.43%, BNGO is doing worse than 96.49% of the companies in the same industry.
BNGO has a Return On Equity of -277.86%. This is amonst the worse of the industry: BNGO underperforms 89.47% of its industry peers.
Industry RankSector Rank
ROA -155.43%
ROE -277.86%
ROIC N/A
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BNGO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNGO has more shares outstanding than it did 1 year ago.
BNGO has more shares outstanding than it did 5 years ago.
BNGO has a worse debt/assets ratio than last year.

2.2 Solvency

BNGO has an Altman-Z score of -13.29. This is a bad value and indicates that BNGO is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.29, BNGO is not doing good in the industry: 94.74% of the companies in the same industry are doing better.
BNGO has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
BNGO has a better Debt to Equity ratio (0.07) than 68.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -13.29
ROIC/WACCN/A
WACC15.7%

2.3 Liquidity

A Current Ratio of 1.43 indicates that BNGO should not have too much problems paying its short term obligations.
BNGO has a Current ratio of 1.43. This is in the lower half of the industry: BNGO underperforms 77.19% of its industry peers.
A Quick Ratio of 0.99 indicates that BNGO may have some problems paying its short term obligations.
BNGO has a Quick ratio of 0.99. This is amonst the worse of the industry: BNGO underperforms 82.46% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.99

More info and screens

6

3. Growth

3.1 Past

BNGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.51%, which is quite impressive.
The Revenue has decreased by -0.85% in the past year.
Measured over the past years, BNGO shows a very strong growth in Revenue. The Revenue has been growing by 24.65% on average per year.
EPS 1Y (TTM)67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Sales Q2Q%-34.83%

3.2 Future

The Earnings Per Share is expected to grow by 15.17% on average over the next years. This is quite good.
The Revenue is expected to grow by 30.99% on average over the next years. This is a very strong growth
EPS Next Y64.63%
EPS Next 2Y38.49%
EPS Next 3Y24.56%
EPS Next 5Y15.17%
Revenue Next Year-19.65%
Revenue Next 2Y-7.64%
Revenue Next 3Y1.37%
Revenue Next 5Y30.99%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNGO. In the last year negative earnings were reported.
Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BNGO's earnings are expected to grow with 24.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.49%
EPS Next 3Y24.56%

More info and screens

0

5. Dividend

5.1 Amount

BNGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONANO GENOMICS INC

NASDAQ:BNGO (12/26/2024, 2:19:38 PM)

0.2093

+0.01 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners11.76%
Inst Owner Change-16.11%
Ins Owners0.09%
Ins Owner Change-0.07%
Market Cap21.35M
Analysts48.89
Price Target1.02 (387.34%)
Short Float %12.43%
Short Ratio4.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.25%
Min EPS beat(2)-86.74%
Max EPS beat(2)48.24%
EPS beat(4)3
Avg EPS beat(4)9.48%
Min EPS beat(4)-86.74%
Max EPS beat(4)53.93%
EPS beat(8)3
Avg EPS beat(8)-0.45%
EPS beat(12)4
Avg EPS beat(12)-6.7%
EPS beat(16)6
Avg EPS beat(16)-7.43%
Revenue beat(2)0
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-24.19%
Max Revenue beat(2)-4.8%
Revenue beat(4)1
Avg Revenue beat(4)-7.12%
Min Revenue beat(4)-24.19%
Max Revenue beat(4)1.24%
Revenue beat(8)4
Avg Revenue beat(8)-3.25%
Revenue beat(12)7
Avg Revenue beat(12)-0.7%
Revenue beat(16)11
Avg Revenue beat(16)1.63%
PT rev (1m)-47.37%
PT rev (3m)-84.21%
EPS NQ rev (1m)-8.11%
EPS NQ rev (3m)61.91%
EPS NY rev (1m)-14.43%
EPS NY rev (3m)-2.69%
Revenue NQ rev (1m)-24.76%
Revenue NQ rev (3m)-45.04%
Revenue NY rev (1m)-18.29%
Revenue NY rev (3m)-22.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.64
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.33
BVpS0.48
TBVpS0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -155.43%
ROE -277.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.47%
Cap/Sales 2.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.99
Altman-Z -13.29
F-Score2
WACC15.7%
ROIC/WACCN/A
Cap/Depr(3y)20.33%
Cap/Depr(5y)13.26%
Cap/Sales(3y)5.97%
Cap/Sales(5y)3.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60%
EPS Next Y64.63%
EPS Next 2Y38.49%
EPS Next 3Y24.56%
EPS Next 5Y15.17%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Sales Q2Q%-34.83%
Revenue Next Year-19.65%
Revenue Next 2Y-7.64%
Revenue Next 3Y1.37%
Revenue Next 5Y30.99%
EBIT growth 1Y39.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.48%
EBIT Next 3Y24.75%
EBIT Next 5YN/A
FCF growth 1Y21.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.46%
OCF growth 3YN/A
OCF growth 5YN/A